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Identity 
Other names: BAF180, PB1 
HGNC (Hugo): PBRM1 
Location: 3p21.1 
Local order: The PBRM1 gene is located between 




PBRM1 gene is located on chromosome 3p21.1 and 
spans 140566 base pairs on the minus DNA strand. 
Transcription 
20 transcripts have been annotated for the PBRM1 gene
(according to Ensembl as of February 2013), which 
consists of 30 exons. 
Pseudogene 
PBRM1 pseudogenes are not known. 
Protein 
Description 
Human PBRM1 gene encodes an 1582 amino acid 
protein, also referred to as BAF180.  
Six bromodomains (BD1-6), known to recognize 
acetylated lysine residues and frequently found in 
chromatin-associated proteins, constitute the N-
terminal half of PBRM1.  
The C-terminal half of PBRM1 contains two bromo-
adjacent homology (BAH) domains (BAH1 and 
BAH2), present in some proteins involved in 
transcription regulation.  
High mobility group (HMG) domain is located close to 
the C-terminus of PBRM1.  
HMG domains are found in a number of factors 
regulating DNA-dependent processes where HMG 
domains often mediate interactions with DNA. 
 
 
Location of PBRM1 gene on chromosome 3 p21.1. PBRM1 gene is indicated in red, neighbouring genes in blue. Arrows indicate 
direction. 
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The exon-intron organisation of the PBRM1 gene. Exons are shown as dark blue boxes and broken lines connecting the exons 
indicate introns. Exon and intron sizes are in scale. 
 
Schematic diagram of the PBRM1 (BAF180) protein. BD1-6: bromodomain 1-6; BAH1 and BAH2: bromo-adjacent homology domains 
1 and 2; HMG: high mobility group domain. 
 
Expression 
PBRM1 is ubiquitously expressed during mouse 
embryonic development (Wang et al., 2004), and has 
been detected in various human tissues including 
pancreas, kidney, skeletal muscle, liver, lung, placenta, 
brain, heart, intestine, ovaries, testis, prostate, thymus 
and spleen (Xue et al., 2000; Horikawa and Barrett, 
2002). 
Localisation 
PBRM1 protein localises to the nucleus of cells 
(Nicolas and Goodwin, 1996).  
As a component of the PBAF chromatin-remodelling 
complex, it associates with chromatin (Thompson, 
2009), and has been reported to confer the localisation 
of PBAF complex to the kinetochores of mitotic 
chromosomes (Xue et al., 2000). 
Function 
PBRM1/BAF180 functions in the regulation of gene 
expression as a constituent of the evolutionary-
conserved SWI/SNF chromatin remodelling complexes 
(Euskirchen et al., 2012). Beside BRD7 and BAF200, 
PBRM1 is one of the unique components of the 
SWI/SNF-B complex also known as polybromo/BRG1-
associated factors (or PBAF), absent in the SWI/SNF-A 
(BAF) complex (Xue et al., 2000; Brownlee et al., 
2012). On that account, and because it contains 
bromodomains known to mediate binding to acetylated 
histones, PBRM1 has been postulated to target PBAF 
complex to specific chromatin sites, therefore 
providing the functional selectivity for the complex 
(Xue et al., 2000; Lemon et al., 2001; Brownlee et al., 
2012). Although direct evidence for PBRM1 
involvement is lacking, SWI/SNF complexes have also 
been shown to play a role in DNA damage response 
(Park et al., 2006). 
In vivo studies have shown that PBRM1 deletion leads 
to embryonic lethality in mice, where PBRM1 is 
required for mammalian cardiac chamber maturation 
and coronary vessel formation (Wang et al., 2004; 
Huang et al., 2008). 
More recently, PBRM1 has acceded the continuously 
growing group of SWI/SNF subunits  
frequently mutated in cancer (Wilson and Roberts, 
2011; Shain and Pollack, 2013). PBRM1 mutations are 
most predominant in renal cell carcinomas detected in 
over 40% of cases, placing PBRM1 second (after VHL) 
on the list of most frequently mutated genes in this 
cancer (Varela et al., 2011; Hakimi et al., 2013; Peña-
Llopis et al., 2012; Pawlowski et al., 2013).  
PBRM1 mutations have also been found in a smaller 
group of breast and pancreatic cancers (Xia et al., 2008; 
Shain et al., 2012; Numata et al., 2013). Therefore, 
PBRM1 is considered a novel tumour suppressor in 
these cancers. 
Homology 
PBRM1 protein is highly conserved across animal 




Germinal mutations of PBRM1 have not been reported. 
Somatic 
PBRM1 mutations have been found in a large fraction 
of clear cell renal cell carcinomas (Varela et al., 2011; 
Duns et al., 2012; Hakimi et al., 2013), and to a sm ller 
extend also in breast (Xia et al., 2008; Shain and 
Pollack, 2013) and pancreatic cancers (Numata et al., 
2013; Shain and Pollack, 2013).  
The vast majority of PBRM1 mutations found in renal 
and breast cancers are truncating (nonsense, frameshift 
insertions and deletions) (Varela et al., 2011; Hakimi et 
al., 2013). 
Implicated in 
Renal cell carcinoma (RCC) 
Note 
PBRM1 mutations and/or loss of protein expression 
have been reported in a large portion of clear cell
subtype of RCC (Varela et al., 2011; Duns et al., 2012; 
Hakimi et al., 2013; Peña-Llopis et al., 2012; 
Pawlowski et al., 2013).  
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Therefore, PBRM1 has been postulated to function as a 
tumour suppressor and the second major RCC cancer 
gene after VHL. PBRM1 mutations are largely 
mutually exclusive with BAP1 mutations (Peña-Llopis 
et al., 2012; Kapur et al., 2013). 
Prognosis 
PBRM1 mutations are more common in patients with 
advance stages (Hakimi et al., 2013) and loss of 
PBRM1 protein expression has been associated with 
advanced tumour stage, low differentiation grade and
worse patient outcome (Pawlowski et al., 2013).  
In another study, no correlation between PBRM1 statu  
and tumour grade was found (Peña-Llopis et al., 2012).  
Although PBRM1-mutant tumours are associated with 
better prognosis than BAP1-mutant tumours, tumours 
mutated for both PBRM1 and BAP1 exhibit the 
greatest aggressiveness (Kapur et al., 2013). 
Breast cancer 
Note 
Truncating mutations have been identified in a minority 
of breast cancers (Xia et al., 2008). In their study, 
authors showed inhibition of cell proliferation upon 
PBRM1 re-introduction into a mutant cell line, thus 
providing direct evidence for tumour suppressing role 
of PBRM1 in breast cancer. 
Pancreatic cancer 
Note 
Mutations in PBRM1 have been reported in a small 
fraction of pancreatic cancer samples (Numata et al., 
2013). 
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